UWC Cancer TB Screening Innovation: Groundbreaking Low-Cost Test for Cancer, TB, and Long COVID

Revolutionizing Diagnostics: UWC's SensorLab Unveils Multi-Disease Screening Breakthrough

At the University of the Western Cape (UWC), a team of dedicated researchers has pioneered a transformative innovation in healthcare diagnostics. This low-cost, portable electrochemical biosensor, developed at UWC's renowned SensorLab, targets three pressing health threats in South Africa: tuberculosis (TB), various cancers, and long COVID. By detecting specific biomarkers in tiny blood samples, the device promises rapid results that could enable earlier interventions, potentially saving countless lives in resource-limited settings.91

South Africa grapples with a quadruple burden of disease, including infectious ailments like TB and emerging post-viral conditions such as long COVID, alongside rising non-communicable diseases like cancer. Traditional diagnostic methods often involve costly equipment, lengthy lab processing, and specialized personnel, leaving many in rural and underserved communities undiagnosed until it's too late. This UWC innovation addresses these gaps head-on, aligning advanced nanotechnology with the nation's unique healthcare challenges.

🔬 The Science Behind the Biosensor: Step-by-Step Breakdown

The UWC low-cost test operates on electrochemical sensing principles, leveraging nanotechnology to create a highly sensitive platform. Here's how it works in simple terms:

• A small blood sample (or serum) is applied to the sensor's electrode surface, coated with biomarker-specific probes.
• Target biomarkers bind to these probes, triggering an electrochemical reaction that generates a measurable electrical signal, often amplified by light-based detection for precision.
• The portable reader interprets the signal in minutes, displaying results comparable to lab standards but without the infrastructure.90

This process contrasts sharply with conventional tests: TB diagnosis via GeneXpert cartridges costs around R800-R1,000 per test and requires powered machines, while cancer biopsies demand invasive procedures and weeks of wait time. The biosensor's detection limit for SARS-CoV-2 spike protein reaches 0.04 picograms per milliliter (pg/mL)—far surpassing many PCR assays—making it ideal for hidden infections.

Tackling TB: A Game-Changer for South Africa's Leading Killer

Tuberculosis remains South Africa's deadliest infectious disease, with approximately 249,000 new cases and 54,000 deaths reported in 2024 alone. The UWC biosensor detects interferon gamma (IFN-γ), a key immune marker signaling active TB infection, building on 2024 research validations. In poorer communities, where lab access is scarce, delayed diagnosis fuels transmission.

Early detection via this tool could integrate seamlessly into primary clinics, supporting South Africa's National Strategic Plan for TB, which aims for a 44% incidence reduction by 2030. Prof Emmanuel Iwuoha, SensorLab director and supervisor, emphasizes its potential to bolster community health workers with point-of-care reliability.

For those pursuing careers in infectious disease research, opportunities abound at institutions like UWC. Explore research jobs or research assistant positions to contribute to such vital work.

Cancer Detection: Spotting the Silent Threat Early

Cancer incidence in South Africa exceeds 100,000 new cases annually, with breast, ovarian, and gastric types disproportionately affecting underserved populations. The biosensor identifies elevated levels of CapG (macrophage-capping protein), a biomarker overexpressed in these cancers, signaling presence or progression.91

Unlike imaging or biopsies costing thousands of rands, this rapid screen offers a non-invasive first step, flagging high-risk individuals for follow-up. Dr Jaymi Leigh January's PhD work demonstrated its efficacy in human serum, paving the way for scalable screening programs.

Photo by National Cancer Institute on Unsplash

Long COVID: Unmasking Persistent Viral Reservoirs

Post-COVID conditions, or long COVID, affect up to 41% of African patients, manifesting as fatigue, dyspnea, and cognitive issues. The UWC test excels here by pinpointing SARS-CoV-2 spike protein remnants, indicating ongoing viral activity even after negative PCR results.

In South Africa, where COVID overwhelmed systems, this could stratify at-risk patients for targeted therapies, reducing long-term disability burdens estimated at billions in lost productivity.

Read the full UWC announcement for peer-reviewed insights from Bioelectrochemistry.

Meet the Innovators: Dr Jaymi January and the SensorLab Team

Dr Jaymi Leigh January, DSTI–Dr Ivy Matsepe-Casaburri Fellowship recipient, led this PhD project under Prof Iwuoha (UWC Chemistry) and Prof Jan Gettemans (University of Ghent). Collaborators include Dr Nelia Sanga and Olivier Zwaenepoel. SensorLab, founded in 2002, boasts over 100 PhD alumni and specializes in nanotech for health and environment.

"This research addresses South Africa's urgent need for accessible diagnostics," says Dr January, highlighting equity in disease-burdened communities.

Aspiring academics can rate educators like these via Rate My Professor or pursue lecturer jobs in chemistry and biosciences.

Challenges Overcome and Validation Milestones

Developing the biosensor required overcoming biomarker stability issues and serum interference. Lab tests confirmed reproducibility across wide ranges, with real-world serum viability. Published in Bioelectrochemistry, it advances from proof-of-concept toward clinical trials.

• 2024: IFN-γ for TB validated.
• Recent: Spike protein at ultra-low limits.
• Ongoing: CapG integration for multi-panel use.

This positions UWC as a hub for translational research. For career advice, visit higher ed career advice.

Healthcare Impacts: Equity, Cost Savings, and System Relief

In South Africa, diagnostics disparities exacerbate inequalities. The UWC test slashes costs—potentially under R100 per use—and empowers clinics, easing public sector strain. Benefits include:

• Reduced transmission via TB early alerts.
• Cancer survival boosts from prompt referrals.
• Long COVID management to curb chronic care demands.

Stakeholders like the NICD praise such innovations for real-time TB tracking synergies.

MedicalBrief analysis underscores rollout feasibility.90

Photo by National Cancer Institute on Unsplash

Future Outlook: Trials, Commercialization, and Global Reach

Next steps involve field trials in Western Cape clinics, regulatory approvals, and partnerships for mass production. Prof Iwuoha's vision: a multi-disease chip for broader screening. Globally, it could aid low-resource nations facing similar burdens.

For researchers eyeing postdocs, check postdoc opportunities. UWC exemplifies South African higher ed excellence.

Careers in Biosensor Research: Join the Next Wave

UWC's success highlights thriving fields like nanotechnology and diagnostics. With SA's health R&D investments rising, roles in labs like SensorLab abound. Tailor your CV via free resume template and explore university jobs.

In summary, this innovation not only advances science but inspires the next generation. Engage with professors on Rate My Professor, browse higher ed jobs, or seek career advice to get involved.